 |
|
|
REFERENCES
1.
Lanzkowsy P: Manual of Pediatric Hematology and
Oncology, 2nd ed. New York, Churchill Livingstone, 1995.
2.
Kabalin JN: Anatomy of the retroperitoneum and
the kidney. In Walsh PC, Retik AB, Staurey TA, Vaughan
ED (eds): Campbell's Urology, 7th ed. Philadelphia, WB Saunders, 1998.
3.
Taragho EA: Anatomy of the lower urinary tract.
In Walsh PC, Retik AB, Staurey TA, Vaughan ED (eds):
Campbell's Urology, 7th ed. Philadelphia, WB Saunders, 1998.
4.
Hemmings HC Jr: Anesthesia, adjuvant drugs and
the kidney. In Malhotra V (ed): Anesthesia for
Renal and Genitourinary Surgery. New York, McGraw-Hill, 1996, p 18.
5.
Kassirer JP: Clinical evaluation of kidney function-glomerular
function. N Engl J Med 285:385, 1971.
6.
Elkington JR, Huth EJ, Webster GD Jr, et al: The
renal excretion of hydrogen ion in renal tubular acidosis. I. Quantitative assessment
of the response to ammonium chloride as an acid load. Am J Med 29:554, 1960.
7.
Erslev AJ, Shapiro SS: Hematologic aspects of renal
failure. In Strauss MB, Welt LG (eds): Diseases
of the Kidney. Boston, Little, Brown, 1988, p 273.
8.
Fisher JW: Introduction to a conference on erythropoietin.
Ann N Y Acad Sci 149:9, 1968.
9.
Adamson JW, Eschbach J, Finch CA: The kidney and
erythropoiesis. Am J Med 44:725, 1978.
10.
May RC, Mitch WE: The pathophysiology of uremia.
In Brenner BM, Rector FC Jr (eds): The Kidney,
5th ed. Philadelphia, WB Saunders, 1996, p 2148.
11.
Goldman: Cecil Textbook of Medicine, Renal and
Genitourinary Diseases, 21st ed. Philadelphia, WB Saunders, 2000, pp 536–542.
12.
Goudsouzian NG, Karamanian A: The electrocardiogram.
In Physiology for the Anesthesiologist. Norwalk,
CT, Appleton-Century-Crofts, 1977, p 37.
13.
Gottlieb RH, Weinberg EP, Rubens DJ, et al: Renal
sonography: Can it be used more selectively in the setting of an elevated serum
creatine level? Am J Kidney Dis 29:362–367, 1997.
14.
Rutsky EA, Rostand SG: Treatment of uremic pericarditis
and pericardia effusion. Am J Kidney Dis 10:2–8, 1987.
15.
Figueroa W, Alankar S, Pai N, et al: Subxiphoid
pericardial window for pericardial effusion in end-stage renal disease. Am J Kidney
Dis 27:664–667, 1996.
16.
Prough DS, Foreman AS: Anesthesia and the renal
system. In Barash PG, Cullen BF, Stoelting RK (eds):
Clinical Anesthesia, 2nd ed. Philadelphia, JB Lippincott, 1992, pp 1125–1156.
17.
Mann JF: What are the short-term and long-term
consequences of anaemia in CRF patients? Nephrol Dial Transplant 14(Suppl 2):29–36,
1999.
18.
Winearls CG: Recombinant human erythropoietin:
10 years of clinical experience. Nephrol Dial Transplant 13(Suppl 2):3–8,
1998.
19.
Mannucci PM, Remuzzi G, Pusineri F, et al: Deamino-8-D-arginine
vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8–12, 1983.
20.
Anderson RJ, Gambertoglio JG, Schier RW: Clinical
Use of Drugs in Renal Failure. Springfield, IL, Charles C Thomas, 1976.
21.
Prescot LF: Mechanisms of renal excretion of drugs
(with special reference to drugs used by anaesthetists). Br J Anaesth 44:246, 1972.
22.
Olsen GD, Bennett WM, Porter GA: Morphine and
phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol
Ther 17:677, 1975.
23.
Stanski DR, Watkins WD: Drugs Disposition in Anesthesia.
Orlando, FL, Grune & Stratton, 1982.
24.
Yeh SY: Urinary excretion of morphine and its
metabolites in morphine dependent subjects. J Pharmacol Exp Ther 192:201, 1975.
25.
Spector S, Vessel ES: Disposition of morphine
in man. Science 74:421, 1972.
26.
Don HF, Dieppa RA, Taylor P: Narcotic analgesics
in anuric patients. Anesthesiology 42:745, 1975.
27.
Mather LE, Meffin PJ: Clinical pharmacokinetics
of pethidine. Clin Pharmacokinet 3:352, 1978.
28.
Verbeeck RK, Branch RA, Wilkinson GR: Meperidine
disposition in man: Influence of urinary pH and route of administration. Clin Pharmacol
Ther 30:619, 1981.
29.
McClain DA, Hug CC: Intravenous fentanyl kinetics.
Clin Pharmacol Ther 28:106, 1980.
30.
Hug CC, Murphy MR: Tissue redistribution of fentanyl
and its termination of effects in rats. Anesthesiology 55:369, 1981.
31.
Davis PJ, Stiller RL, Cook DR: Pharmacokinetics
of sufentanil in adolescent patents with chronic renal failure. Anesth Analg 67:268,
1988.
32.
Davis PJ, Stiller RL, Cook DR: Effects of cholestatic
hepatic disease and chronic renal failure on alfentanil pharmacokinetics in children.
Anesth Analg 68:579, 1989.
33.
Hoke JF, Schlugman D, Dershwitz M, et al: Pharmacokinetics
and pharmacodynamics of remifentanil in persons with renal failure compared with
healthy volunteers. Anesthesiology 87:533, 1997.
34.
Mazze RI: Metabolism of the inhaled anaesthetics:
Implications of enzyme induction. Br J Anaesth 56:275, 1985.
35.
Mazze RI, Trudell JR, Cousins MJ: Methoxyflurane
metabolism and renal dysfunction: Clinical correlation in man. Anesthesiology 35:247,
1971.
36.
Cousins M, Mazze RI: Methoxyflurane nephrotoxicity:
A study of dose response in man. JAMA 255:1611, 1973.
37.
Mazze RI, Sievenpiper TS, Stevenson J: Renal effects
of enflurane and halothane in patients with abnormal renal function. Anesthesiology
60:161, 1984.
38.
Mazze RI, Cousins MJ, Barr GA: Renal effects and
metabolism of isoflurane in man. Anesthesiology 40:536, 1974.
39.
Eger EI II: Stability of I-653 in soda-lime.
Anesth Analg 66:983, 1987.
40.
Koblin DD, Eger EI II, Johnson BH, et al: I-653
resists degradation in rats. Anesth Analg 67:534, 1988.
41.
Koblin DD, Wesikopf RB, Holmes MA, et al: Metabolism
of I-653 and isoflurane in swine. Anesth Analg 68:147, 1989.
42.
Jones RM, Koblin DD, Cashman JN, et al: Biotransformation
and hepato-renal function in volunteers after exposure to desflurane (I-653). Br
J Anaesth 64:482, 1990.
43.
Weiskopf RB, Eger EI II, Ionescu P, et al: Desflurane
does not produce hepatic or renal injury in human volunteers. Anesth Analg 74:570,
1992.
44.
Hanaki C, Fujii K, Mono M, Tashima T: Decomposition
of sevoflurane by soda-lime. Hiroshima J Med Sci 36:61, 1987.
45.
Kobayashe Y, Ochiai R, Takeda J, et al: Serum
and urinary inorganic fluoride levels after prolonged inhalation of sevoflurane in
man. Anesthesiology 75:A348, 1991.
46.
Jones RM: Clinical comparison of inhalation anesthetic
agents. Br J Anaesth 56:57S, 1984.
47.
Holaday DA, Smith FR: Clinical characteristics
and biotransformation of sevoflurane in healthy human volunteers. Anesthesiology
54:100, 1981.
48.
Priano LL: Effect of halothane on renal hemodynamics
during normovolemia and hemorrhagic hypovolemia. Anesthesiology 63:357, 1985.
49.
Gelman S, Fowler KC, Smith LR: Regional blood
flow during isoflurane and halothane anesthesia. Anesth Analg 63:557, 1984.
50.
Merin RG, Bernard JM, Doursout MR: Comparison
of the effects of isoflurane and desflurane on cardiovascular dynamics and regional
blood flow in the chronically instrumented dog. Anesthesiology 74:568, 1991.
51.
Cousin MJ, Greenstein LR, Hitt BA, Mazze RI: Metabolism
and renal effects of enflurane in man. Anesthesiology 44:44, 1976.
52.
Cook TL, Beppu WJ, Hitt BA, et al: Renal effects
and metabolism of sevoflurane in Fischer 344 rats. Anesthesiology 43:70, 1975.
53.
Ghoneim MM, Pandya HB, Kelley SE, et al: Binding
of thiopental to plasma proteins: Effects on distribution in the brain and heart.
Anesthesiology 45:635, 1976.
54.
Burch PG, Stanski DR: Decreased protein binding
and thiopental kinetics. Clin Pharmacol Ther 32:212, 1982.
55.
Dundee JW, Richards RK: Effect of azotemia upon
the action of intravenous barbiturate anesthesia. Anesthesiology 15:333, 1954.
56.
Breimer DD: Pharmacokinetics of methohexitone
following intravenous infusion in humans. Br J Anaesth 48:643, 1976.
57.
Hudson RJ, Stanski DR, Burch PG: Pharmacokinetics
of methohexital and thiopental in surgical patients. Anesthesiology 59:215, 1983.
58.
Masuda A, Asahi T, Sakamaki M, et al: Uric acid
excretion increases during propofol anesthesia. Anesth Analg 85:144–148, 1997.
59.
Thomas JL, Holmes JH: Effect of hemodialysis on
plasma cholinesterase. Anesth Analg 49:323, 1970.
60.
Wyant GM: The anesthetist looks at tissue transplantation:
Three years' experience with kidney transplants. Can J Anaesth 14:255, 1967.
61.
Ryan DW: Preoperative serum cholinesterase concentration
in chronic renal failure. Br J Anaesth 49:945, 1977.
62.
Desmond JW, Gordon RA: The effect of haemodialysis
on blood volume and plasma cholinesterase levels. Can J Anaesth 16:292, 1969.
63.
Mazze RI, Escue HM, Houston JB: Hyperkalemia and
cardiovascular collapse following administration of succinylcholine to the traumatized
patient. Anesthesiology 31:540, 1969.
64.
Gronert GA, Theye RA: Pathophysiology of hyperkalemia
induced by succinylcholine. Anesthesiology 43:89, 1975.
65.
Miller RD, Way WL, Hamilton WK, et al: Succinylcholine
induced hyperkalemia in patients with renal failure? Anesthesiology 36:138, 1972.
66.
Koide M, Waud BE: Serum potassium concentrations
after succinylcholine in patients with renal failure. Anesthesiology 36:142, 1972.
67.
Matteo RS, Nishitateno K, Pau EK, et al: Pharmacokinetics
of d-tubocurarine in man: Effect of an osmotic diuretic
on urinary excretion. Anesthesiology 52:335, 1980.
68.
Sheiner LB, Stanski DR, Vozek S, et al: Simultaneous
modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.
Clin Pharmacol Ther 25:358, 1979.
69.
Ghoneim MM, Kramer E, Bannow R, et al: Binding
of tubocurarine to plasma proteins in normal man and in patients with hepatic or
renal failure. Anesthesiology 39:410, 1979.
70.
Miller RD, Matteo RS, Benet LZ, et al: The pharmacokinetics
of d-tubocurarine in man with or without renal failure.
J Pharmacol Exp Ther 202:1, 1977.
71.
Gibaldi M, Levy G, Hayton WL: Tubocurarine and
renal failure. Br J Anaesth 44:163, 1972.
72.
Brotherton WP, Matteo RS: Pharmacokinetics and
pharmacodynamics of metocurarine in humans with and without renal failure. Anesthesiology
55:273, 1981.
73.
Agoston S, Vermeer GA, Kersten UW, et al: The
fate of pancuronium and its metabolites in anesthetized man. J Pharmacol Exp Ther
207:539, 1978.
74.
Miller RD, Agoston S, Booij LHDJ, et al: The comparative
potency and pharmacodynamics of pancuronium and its metabolites in anesthetized man.
J Pharmacol Exp Ther 207:539, 1978.
75.
Somogyi AA, Shanks CA, Triggs EJ: The effect of
renal failure on the disposition and neuromuscular blocking action of pancuronium
bromide. Eur J Clin Pharmacol 12:23, 1977.
76.
McLeod K, Watson MJ, Rawlins MD: Pharmacokinetics
of pancuronium in patients with normal and impaired renal function. Br J Anaesth
48:341, 1976.
77.
Hughes R, Chapple DJ: The pharmacology of atracurium:
A new competitive neuromuscular blocking agent. Br J Anaesth 53:31, 1981.
78.
Fahey MR, Rupp SM, Fisher DM, et al: The pharmacokinetics
and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology
61:699, 1984.
79.
Kisor DF, Schmith VD, Wargin WA, et al: Importance
of the organ-independent elimination of cisatracurium. Anesth Analg 83:901, 1996.
80.
Orko R, Heino A, Bjorksten F, et al: Comparison
of atracurium and vecuronium in anaesthesia for renal transplantation. Acta Anaesthesiol
Scand 31:450, 1987.
81.
Kisor DF, Schmith VD, Wargin WA, et al: Importance
of the organ-independent elimination of cisatracurium. Anesth Analg 83:1065, 1996.
82.
Lynam DP, Cronnelly R, Castagnoli KP, et al: The
pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with
isoflurane with normal renal function or with renal failure. Anesthesiology 69:227,
1988.
83.
Bencini AF, Scaf AHJ, Sohn YJ, et al: Disposition
and urinary excretion of vecuronium bromide in anesthetized patients with normal
renal function or renal failure. Anesth Analg 65:245, 1986.
84.
Gramstad L, Gjerlow JA, Hysing ES, Rugstad HE:
Interaction of cyclosporin and its solvent, Cremophor, with atracurium and vecuronium:
Studies in the cat. Br J Anaesth 58:1149, 1986.
85.
Cashman JN, Luke JJ, Jones RM: Neuromuscular block
with doxacurium (BW A938 U) in patients with normal or absent renal function. Br
J Anaesth 64:186, 1990.
86.
Cook DR, Freeman JA, Lai AA, et al: Pharmacokinetics
and pharmacodynamics of doxacurium in normal patients and in those with liver or
renal failure. Anesth Analg 72:145, 1991.
87.
Caldwell JE, Canfell PC, Castagnoli KP, et al:
The influence of renal failure on the pharmacokinetics and duration of action of
pipecuronium bromide in patients anesthetized with halothane and nitrous oxide.
Anesthesiology 70:7, 1989.
88.
Cook DR, Freeman JA, Lai AA, et al: Pharmacokinetics
of mivacurium in normal patients and in those with hepatic or renal failure. Br
J Anaesth 69:580, 1992.
89.
Phillips BJ, Hunter JM: Use of mivacurium chloride
by constant infusion in the anephric patient. Br J Anaesth 69:492, 1992.
90.
Mangar D, Kirchoff GT, Rose PL, Castellano FC:
Prolonged neuromuscular block after mivacurium in a patient with end stage renal
disease. Anesth Analg 76:866, 1993.
91.
Szenohradsky J, Fisher DM, Segredo V, et al: Pharmacokinetics
of rocuronium bromide (ORG 9426) in patients with normal renal function or patients
undergoing cadaver renal transplantation. Anesthesiology 77:899, 1992.
92.
Cronnelly R, Stanski DR, Miller RD, et al: Renal
function and the pharmacokinetics of neostigmine in anesthetized man. Anesthesiology
51:222, 1979.
93.
Cronnelly R, Stanski DR, Miller RD, et al: Pyridostigmine
kinetics with and without renal function. Clin Pharmacol Ther 28:78, 1980.
94.
Morris RB, Cronnelly R, Miller RD, et al: Pharmacokinetics
of edrophonium in anephric and renal transplant patients. Br J Anaesth 53:1311,
1981.
95.
Koup JR, Greenblatt DJ, Jusko WJ, et al: Pharmacokinetics
of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet
Biopharm 3:181, 1975.
96.
Iisalo E, Dahl M, Sundquist H: Serum digoxin in
adults and children. Int J Clin Pharmacol 7:219, 1973.
97.
Beermann B, Groschinsky-Grind M, Rosen A: Absorption,
metabolism and excretion of hydrochlorothiazide. Clin Pharmacol Ther 19:531, 1976.
98.
Smith DE, Brater DC, Lin ET, et al: Attenuation
of furosemide diuretic effect by indomethacin: Pharmacokinetics evaluation. J Pharmacokinet
Biopharm 7:265, 1979.
99.
Kornhauser DM, Wood AJJ, Vesta RE, et al: Biological
determinants of propranolol disposition in man. Clin Pharmacol Ther 23:165, 1978.
100.
Henry PD: Comparative pharmacology of calcium
antagonists: Nifedipine, verapamil and diltiazem. Am J Cardiol 46:1047, 1980.
101.
Kwan KC, Foltz EL, Breault GO, et al: Pharmacokinetics
of methyldopa in man. J Pharmacol Exp Ther 198:264, 1976.
102.
Miller RD, Way WL, Eger EI II: The effects of
alpha-methyldopa, reserpine, guanethidine and iproniazid on minimum alveolar anesthetic
requirement (MAC). Anesthesiology 29:1153, 1968.
103.
McMartin C, Simpson P: The absorption and metabolism
of guanethidine in hypertensive patients requiring different doses of the drug.
Clin Pharmacol Ther 12:73, 1971.
104.
Neurath GB, Dunger M: Blood levels of the metabolites
of glyceryl trinitrate and pentaerythritol tetranitrate after administration of a
two-step preparation. Arzneimittelforschung 27:416, 1977.
105.
Smith RP: Cyanate and thiocyanate: Acute toxicity.
Proc Soc Exp Biol Med 142:1041, 1973.
106.
Talseth T: Studies on hydralazine. III. Bioavailability
of hydralazine in man. Eur J Clin Pharmacol 10:395, 1976.
107.
Talseth T: Studies on hydralazine. II. Elimination
rate and steady state concentration in patients with impaired renal function. Eur
J Clin Pharmacol 10:311, 1976.
108.
Luke DR, Awni WM, Halstenson CE, et al: Bioavailability
of labetalol in patients with end-stage renal disease. Ther Drug Monit 14:203, 1992.
109.
Wiest D: Esmolol: A review of its therapeutic
efficacy and pharmacokinetic characteristics. Clin Pharmacokinet 28:190, 1995.
110.
Levinsky NG, Alexander EA: Acute renal failure.
In Brenner BM, Rector FC Jr (eds): The Kidney,
5th ed. Philadelphia, WB Saunders, 1996.
111.
Vertel RM, Knochel JP: Nonoliguric acute renal
failure. JAMA 200:118, 1967.
112.
Goldman L, Bennett JC: Cecil Textbook of Medicine,
21st ed. Philadelphia, WB Saunders, 2000, pp 567–571.
113.
Brown CB, Cameron JS, Ogg CS, et al: Established
acute renal failure following surgical operations. In
Friedman EA, Eliahue HE (eds): Proceedings of the Conference on Acute Renal Failure,
DHEW Publication No. (NIH) 74-608. Washington, DC, U.S. Government Printing Office,
1973, p 187.
114.
Kolf WJ, Berk HTJ: Artificial kidney dialyzer
with great area. Acta Med Scand 117:121, 1944.
115.
Bromage PR, Gertel M: Brachial plexus anesthesia
in chronic renal failure. Anesthesiology 36:488, 1972.
116.
Martin R, Beauregard MD, Tetrault MD: Brachial
plexus blockade and chronic renal failure. Anesthesiology 69:405, 1988.
117.
Azar I: Transurethral resection of prostate.
In Malhotra V (ed): Anesthesia for Renal and Genitourinary
Surgery. New York, McGraw-Hill, 1996, pp 93–109.
118.
Hatch PD: Surgical and anaesthetic considerations
in transurethral resection of the prostate. Anaesth Intensive Care 15:203, 1987.
119.
Malhotra V: Transurethral resection of the prostate.
Anesthesiol Clin North Am 18:883–897, 2000.
120.
Mebust WK, Holtgreive HL, Cockett ATK, et al:
Transurethral prostatectomy—immediate and postoperative complications. A
cooperative study of 13 participating institutions evaluating 3,885 patients. J
Urol 141:243, 1989.
121.
Beers RA, Kane PB, Nsouli I, et al: Does a mid-lumbar
block level provide adequate anaesthesia for transurethral prostatectomy [abstract]?
Can J Anaesth 41:807, 1994.
122.
Malhotra V, Perlmutter A: Caudal anesthesia provides
effective anesthesia for laser prostatectomy. Reg Anesth 22(2S):93, 1997.
123.
Blake DW: The general vs. regional anesthesia
debate: Time to re-examine the goals. Aust N Z J Surg 65:51, 1995.
124.
Neilsen KK, Andersen K, Asbjorn J, et al: Blood
loss during transurethral resection of the prostate: A comparison of epidural and
general anesthesia [abstract]. Int Urol Nephrol 19:287, 1987.
125.
Sorensen RM, Pace NL: Anesthetic technique during
surgical repair of femoral neck fractures. A meta-analysis [abstract]. Anesthesiology
77:1095, 1992.
126.
Bernstein S, Malhotra V: Regional anesthesia
for genitourinary surgery. In Malhotra V (ed):
Anesthesia for Renal and Genitourinary Surgery. New York, McGraw-Hill, 1996, p 265.
127.
Bowman GW, Hoerth JW, McGlotheen JS: Anesthesia
for transurethral resection of prostate: Spinal or general? J Am Assoc Nurse Anesth
49:63, 1981.
128.
Burrows R: Anesthesia for prostatectomies. Anesth
Analg 228, 1924.
129.
Cullen DJ, Apolone G, Greenfield S, et al: ASA
physical status and age predict morbidity after three surgical procedures [abstract].
Ann Surg 220:3, 1994.
130.
Ashton CM, Lahart CJ, Wray NP: The incidence
of perioperative myocardial infarction with transurethral resection of the prostate
[abstract]. J Am Geriatr Soc 37:614, 1989.
131.
Chung FF, Chung A, Meier RH, et al: Comparison
of perioperative mental function after general anesthesia and spinal anaesthesia
with intravenous sedation. Can J Anaesth 36:382, 1989.
132.
Attalah MM, Hoeft A, El-Ghouri MA, et al: Does
spinal anesthesia affect cerebral oxygenation during transurethral prostatectomy
[abstract]? Reg Anesth Pain Med 23:119, 1998.
133.
Hahn RG: The transurethral resection syndrome—not
yet a finished story [editorial]. Reg Anesth Pain Med 23:115, 1998.
134.
Gravenstein D: Transurethral resection of prostate
(TURP) syndrome: A review of pathophysiology and management. Anesth Analg 84:438,
1997.
135.
Asheim GM: Hyponatremia during transurethral
surgery. Can J Anaesth 20:274, 1973.
136.
Ovassapian A, Joshi CW, Brunner EA: Visual disturbance:
An unusual symptom of transurethral prostatic resection reaction. Anesthesiology
57:332, 1982.
137.
Hahn RG, Essen P: ECG and cardiac enzymes after
glycine absorption in transurethral prostatic resection [abstract]. Acta Anaesthesiol
Scand 38:550, 1994.
138.
Hockstra PT, Kahnoski R, McCamish MA, et al:
Transurethral prostatic resection syndrome—a new perspective: Encephalopathy
with associated hyperammonemia. J Urol 130:704, 1983.
139.
Roesch RP, Stoelting RK, Lingeman JE, et al:
Ammonia toxicity resulting from glycine absorption during a transurethral resection
of the prostate. Anesthesiology 58:577, 1983.
140.
Kenyon HR: Perforation in transurethral operations;
technic for immediate diagnosis and management of extravasations. JAMA 142:798,
1950.
141.
Holtgrewe HL, Valk WL: Factors influencing the
mortality and morbidity of transurethral prostatectomy: A study of 2015 cases.
J Urol 87:450, 1962.
142.
Allen TD: Body temperature changes during prostatic
resection as related to the temperature of the irrigating solution. J Urol 110:433,
1973.
143.
Harioka T, Marakawa M, Noda J, Mori K: Effect
of continuously warmed irrigating fluids during transurethral resection. Anaesth
Intensive Care 16:324–328, 1988.
144.
Heathcote PS, Dyer PM: The effect of warm irrigation
on blood loss during transurethral prostatectomy under spinal anesthesia. Br J Urol
58:669, 1986.
145.
Chow TC, Cho PH: The influence of small dose
intrathecal fentanyl on shivering during transurethral resection of prostate under
spinal anesthesia. Acta Anaesthesiol Sin 32:165, 1994.
146.
Friedman NJ, Hoag MS, Robinson AJ, et al: Hemorrhagic
syndrome following transurethral prostatic resection for benign adenoma. Arch Intern
Med 124:341, 1969.
147.
Chambers FA, Corcoran M, O'Toole DP, et al: The
effects of pre-operative methoxamine on blood loss and hemodynamics during transurethral
prostatic resection under spinal anesthesia. Anesthesiology 79:A161, 1993.
148.
Keoghane SR, Sullivan ME, Doll HA, et al: Five-year
data from the Oxford Laser Prostatectomy Trial. BJU Int 86:227–278, 2000.
149.
Tan AH, Gilling PJ: Holmium laser prostatectomy:
Current techniques. Urology 60:152–156, 2002.
150.
Shingleton WB, Farabaugh P, May W: Three-year
follow-up of laser prostatectomy versus transurethral resection of the prostate in
men with benign prostatic hyperplasia. Urology 60:305–308, 2002.
